Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Dec;37(12):2747–2753. doi: 10.1128/aac.37.12.2747

In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.

S A Marshall 1, R N Jones 1
PMCID: PMC192801  PMID: 8109948

Abstract

DU-6859a was tested against 844 recent clinical isolates (most from bacteremias) by using reference MIC determination procedures. The activity of DU-6859a against members of the family Enterobacteriaceae was comparable to that of ciprofloxacin (range of MICs for 90% of isolates [MIC90], < or = 0.015 to 1 microgram/ml), and the highest MICs were observed among Serratia marcescens and Providencia rettgeri isolates. The DU-6859a MIC90 for Pseudomonas aeruginosa and Xanthomonas maltophilia was 0.5 microgram/ml. Pneumococci (MIC90, 0.06 microgram/ml), Haemophilus influenzae (MIC90, < or = 0.004 microgram/ml), Moraxella catarrhalis (MIC90, < or = 0.015 microgram/ml), and pathogenic neisseriae (MIC90, 0.015 to 0.03 microgram/ml) were very susceptible to DU-6859a. All staphylococci had DU-6859a MICs of < or = 1 microgram/ml, including oxacillin- and ciprofloxacin-resistant strains. DU-6859a was very active against isolates resistant to ceftazidime (MIC90, < or = 0.12 microgram/ml), ciprofloxacin (MIC90, < or = 8 micrograms/ml), and gentamicin (MIC90, < or = 1 microgram/ml).

Full text

PDF
2747

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chin N. X., Clynes N., Neu H. C. Resistance to ciprofloxacin appearing during therapy. Am J Med. 1989 Nov 30;87(5A):28S–31S. doi: 10.1016/0002-9343(89)90015-6. [DOI] [PubMed] [Google Scholar]
  2. Jacoby G. A., Archer G. L. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med. 1991 Feb 28;324(9):601–612. doi: 10.1056/NEJM199102283240906. [DOI] [PubMed] [Google Scholar]
  3. Jones R. N. Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians? Diagn Microbiol Infect Dis. 1992 Feb;15(2):177–179. doi: 10.1016/0732-8893(92)90046-v. [DOI] [PubMed] [Google Scholar]
  4. Jones R. N., Gavan T. L., Thornsberry C., Fuchs P. C., Gerlach E. H., Knapp J. S., Murray P., Washington J. A., 2nd Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. J Clin Microbiol. 1989 Dec;27(12):2758–2766. doi: 10.1128/jcm.27.12.2758-2766.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992 Jul;36(7):1491–1498. doi: 10.1128/aac.36.7.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES